Balderramo Domingo, Mattos Angelo Z, Mulqui Victoria, Chiesa Talita, Plácido-Damián Zuly, Abarca Jaysoom, Bolomo Andrea, Carlino Yanina, Bombassaro Isadora Z, Wiltgen Denusa, Castillo Laura Tenorio, Díaz Karina, Acuña Johana, Manero Estela, Prieto Jhon, Carrera Enrique, Díaz-Ferrer Javier, Debes Jose D
Gastroenterology Department, Hospital Privado Universitario de Córdoba, Instituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina.
Graduate Program in Medicine: Hepatology, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil.
Can J Gastroenterol Hepatol. 2021 Oct 5;2021:1622533. doi: 10.1155/2021/1622533. eCollection 2021.
The role of liver function tests (LFT) as prognostic factors in patients admitted with COVID-19 has not been fully investigated, particularly outside resource-rich countries. We aimed at evaluating the prognostic value of abnormal LFT on admission and during hospitalization of patients with COVID-19.
We performed a retrospective study that included 298 adult patients hospitalized for COVID-19, between 05/2020 and 02/2021, in 6 hospitals from 5 countries in South America. We analyzed demographic and comorbid variables and laboratory tests on admission and during hospitalization. LFT over twice the upper limit of normal (ALEx2) were also evaluated in relation to a variety of factors on admission and during hospitalization. De novo-ALEx2 was defined as the presence of ALEx2 at one week of hospitalization in patients without ALEx2 on admission. Patients were followed until hospital discharge or death. Multivariable analysis was used to evaluate the association between ALEx2 on admission and during hospitalization and mortality.
Of the total of 298 patients, 60% were male, with a mean age of 60 years, and 74% of patients had at least one comorbidity. Of those, 137 (46%) patients were transferred to the intensive care unit and 66 (22.1%) patients died during hospitalization. ALEx2 on admission was present in 87 (29.2%) patients and was found to be independently associated with 1-week mortality (odds ratio (OR) = 3.55; 95% confidence interval (95%CI) 1.05-12.05). Moreover, 84 (39.8%) out of 211 patients without ALEx2 at admission developed de novo-ALEx2, which was independently associated with mortality during second week of hospitalization (OR = 6.09; 95%CI 1.28-29) and overall mortality (OR = 2.93, 95%CI 1.05-8.19).
A moderate elevation of LFT during admission was associated with a poor short-term prognosis in patients hospitalized with COVID-19. In addition, moderate elevation of LFT at one week of hospitalization was an independent risk factor for overall mortality in these patients.
肝功能检查(LFT)作为新冠病毒疾病(COVID-19)患者预后因素的作用尚未得到充分研究,尤其是在资源丰富国家以外的地区。我们旨在评估COVID-19患者入院时及住院期间肝功能异常的预后价值。
我们进行了一项回顾性研究,纳入了2020年5月至2021年2月期间在南美洲5个国家的6家医院因COVID-19住院的298例成年患者。我们分析了人口统计学和合并症变量以及入院时和住院期间的实验室检查结果。还评估了肝功能超过正常上限两倍(ALEx2)与入院时和住院期间各种因素的关系。新发ALEx2定义为入院时无ALEx2的患者在住院一周时出现ALEx2。对患者进行随访直至出院或死亡。采用多变量分析评估入院时和住院期间ALEx2与死亡率之间的关联。
在总共298例患者中,60%为男性,平均年龄60岁,74%的患者至少有一种合并症。其中,137例(46%)患者被转入重症监护病房,66例(22.1%)患者在住院期间死亡。入院时存在ALEx2的患者有87例(29.2%),发现其与1周死亡率独立相关(比值比(OR)=3.55;95%置信区间(95%CI)1.05-12.05)。此外,入院时无ALEx2的211例患者中有84例(39.8%)出现新发ALEx2,这与住院第二周的死亡率独立相关(OR=6.09;95%CI 1.28-29)和总体死亡率(OR=2.93,95%CI 1.05-8.19)。
COVID-19住院患者入院时肝功能轻度升高与短期预后不良相关。此外,住院一周时肝功能轻度升高是这些患者总体死亡的独立危险因素。